Cargando…
Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek...
Autores principales: | Durães, Fernando, Sousa, Emília |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630996/ https://www.ncbi.nlm.nih.gov/pubmed/31010063 http://dx.doi.org/10.3390/ph12020063 |
Ejemplares similares
-
Omadacycline: A Modernized Tetracycline
por: Gallagher, Jason C
Publicado: (2019) -
In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis
por: Sun, Xiang, et al.
Publicado: (2021) -
Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021) -
In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020) -
Sub-growth-inhibitory concentrations of omadacycline inhibit Staphylococcus aureus haemolytic activity in vitro
por: Serio, Alisa W, et al.
Publicado: (2021)